A monocenter registry study to document clinical, biological and quality of life parameters in patients with gastrointestinal tumors

A monocenter registry study to document clinical, biological and quality of life parameters in patients with gastrointestinal tumors - GASTRY

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00018788

Enrollment

450

Registered

2020-01-14

Start date

2020-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal tumors CUP-SYNDROM C15-C26 C80

Interventions

Group 1: Documentation of clinical data including molecular diagnostic results and quality of life in patients with gastrointestinal tumors or unknown primary.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Patients with advanced GI Tumor or CUP Syndrome and indication of systemic treatment • Molecular examination indicated • Age =18 Jahre • Written informed consent

Exclusion criteria

Exclusion criteria: • Severe neurologic or psychiatric disorders which interfere with the patient's ability to provide informed consent

Design outcomes

Primary

Measure	Time frame
Comparison of Overall Survival between patients who received a molecular-stratified therapy after first tumor progression at latest and patients who did not.	—

Secondary

Measure	Time frame
- Comparison of PFS with molecular-stratified therapy and preceding therapy (PFS-Ratio) - Evaluation of efficacy of therapies with pre-defined parameters - Evaluation of Tumor board decisions - Development of a molecular map based on NGS analyses, sub-typing of molecular signalling pathways - Correlation between mutational status and clinical parameters resp. quality of life - Identification of prognostic and predictive factors	—

Measure

Time frame

- Comparison of PFS with molecular-stratified therapy and preceding therapy (PFS-Ratio) - Evaluation of efficacy of therapies with pre-defined parameters - Evaluation of Tumor board decisions - Development of a molecular map based on NGS analyses, sub-typing of molecular signalling pathways - Correlation between mutational status and clinical parameters resp. quality of life - Identification of prognostic and predictive factors

—

Countries

Germany

Contacts

Public ContactJosef Huber

SLK-Kliniken Heilbronn GmbH

josef.huber@slk-kliniken.de+49-7131-49-28700

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 9, 2026